UNSPSC 51111635: Eniluracil

This classification denotes a pyrimidine antagonist and dihydropyrimidine dehydrogenase inhibitor with the molecular formula C6H4N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2E2W0W5XIU, chemically known as 2,4(1h,3h)-pyrimidinedione, 5-ethynyl- but generally known as eniluracil, which bears US NIH Compound Identifier 43157. European Medicines Agency schedules Eniluracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13674MIG.

UNSPSC 51111635 Eniluracil is a Commodity code tracking pharmaceutical procurement—specifically, the active pharmaceutical ingredient and finished-dose formulations of eniluracil, a chemotherapy adjuvant used in cancer treatment regimens. State and local governments buy eniluracil primarily through pharmacy benefit programs, health plans serving state employees and retirees, and Medicaid agencies managing oncology therapeutics. The solicitation activity under this code reflects procurement through both traditional wholesale and direct-to-manufacturer channels, with issuing bodies including state health and human services departments, state employee health plan administrators, and county/municipal health authorities managing pharmacy benefits for covered populations.

The Texas Health and Human Services Commission posted the most recent activity—a Request for Information (RFI) No. HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This RFI signals a shift away from traditional pharmacy benefit manager and group purchasing organization intermediaries toward direct contracting models with manufacturers, including negotiated net pricing without rebates and value-based or outcomes-based payment structures. The RFI targets vendors with experience fulfilling self-insured employer and government health plan requirements in the prior two years and the ability to manage product volume and specialized pharmacy channel partnerships. No award value, timeline, or formal evaluation criteria were specified in the RFI phase; the state characterized this as preliminary market intelligence to inform a subsequent formal RFP. Geographic activity is concentrated in Texas; the source does not support broader interstate procurement patterns for this code.